Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryArizona Complete Health MS Drugs Prior Auth Update…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.1020

    Multiple Sclerosis Drugs (Lemtrada, mitoxantrone)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.1020 alerts

    Get alerted when Policy AZ.CP.PHAR.1020 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, dosing limits, and continuation requirements for alemtuzumab (Lemtrada) and mitoxantrone for Arizona Complete Health (Arizona Medicaid) members.

    Policy Summary
    PayerArizona Complete Health
    PolicyMultiple Sclerosis Drugs (Lemtrada, mitoxantrone)
    Policy CodePolicy AZ.CP.PHAR.1020
    Change TypeAlignment and redirectionstreatment-course limits clarified
    Effective Date11.20.19
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, neurologist prescriber or consult, age, trials of two DMTs, dosing, and supporting clinical records.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Removed certain drugs (e.g., Tysabri, Ocrevus, Ponvory, Tascenso ODT) from this policy and redirected to AHCCCS FFS criteria where applicable.

    Aligned preferred and non-preferred drug lists with AHCCCS FFS PA Guideline and removed references to Care1st and a retired off-label policy.

    Specified limits on treatment courses for certain agents (Lemtrada: one course per authorization; Mavenclad: one course per authorization and two lifetime courses).

    2drugs specifically covered by this policy
    18DMTs listed in Appendix D
    140 mg/m2mitoxantrone lifetime dose limit
    Tysabri,Ocrevus,Ponvory,TascensoDrugs removed from policy
    AlignedPreferred list aligned

    Coverage Criteria for Disease-Modifying Therapies

    Initial Therapy

    Covered when ALL of the following are met

    Initial Approval for Lemtrada or mitoxantrone: 1) Diagnosis of multiple sclerosis (MS);
    2) Prescribed by or in consultation with a neurologist;
    3) Age ≥ 18 years;
    4) Trial and failure (after trial of at least 4 weeks), contraindication, or intolerance to TWO of the specified disease-modifying therapies for MS (document medication, date, and duration);
    5) Drug is not prescribed concurrently with other disease-modifying therapies for MS (see Appendix D);
    Dose limits: 6) Dose does not exceed: a) Lemtrada — first treatment course 12 mg/day for 5 consecutive days (60 mg total); second or subsequent courses 12 mg/day for 3 consecutive days (36 mg total). b) Mitoxantrone — 12 mg/m2 every 3 months with total cumulative lifetime dose limit 140 mg/m2;
    Note: Prior authorization is required for all disease-modifying therapies for MS; if member is currently on Lemtrada or mitoxantrone, refer to Continued Therapy (Section II) with documentation of drug, date, and duration of therapy.

    Continuation Therapy

    Covered when ALL of the following are met

    Continued Therapy for Lemtrada or mitoxantrone: 1) Member meets one of the following: a) Currently receiving medication via Centene benefit or has previously met initial approval criteria; OR b) Documentation supports current receipt of Lemtrada or mitoxantrone as documented by claims history or medical records (document drug, date, and duration of therapy);
    2) Documentation of positive clinical response to therapy;
    3) Drug is not prescribed concurrently with other disease-modifying therapies for MS (see Appendix D);
    4) Dose does not exceed the maximum limits specified in Section I (Initial Approval);
    Note: Approval duration for continued therapy is 12 months. Lemtrada: approval limited to 1 treatment course per authorization as specified under Initial Approval.

    Other Indications

    Other diagnoses/indications

    Other indications: 1) Refer to the AHCCCS FFS Prior Authorization Guideline — Coverage of Off-Label Non-FDA Approved Indications when the diagnosis is not specifically listed under section III;
    2) Mitoxantrone for diagnoses other than multiple sclerosis: refer to CP.PHAR.258 (Mitoxantrone policy);
    3) Tysabri for Crohn's disease: refer to AZ.CP.PHAR.06 (Cytokine and CAM Antagonists policy);
    4) Ofatumumab (Arzerra) for diagnoses other than multiple sclerosis: refer to CP.PHAR.306;
    Operational handling for members already on therapy.

    If member is currently receiving medication via Centene benefit and documentation supports a positive response to therapy, approval duration for other indications is the duration of the request or up to 6 months (whichever is less).

    General coverage alignment and redirections

    Policy-level coverage stance and operational criteria changes

    Policy alignment and redirections: Policy aligns preferred/non-preferred multiple sclerosis drugs with AHCCCS FFS prior authorization guideline and redirects certain agents to AHCCCS FFS criteria; several agents (e.g., Tysabri, Ocrevus, Ponvory, Tascenso ODT and others listed historically) have been removed from this document and should be referred to AHCCCS FFS criteria.
    Operational limits: treatment-course and authorization clarifications have been specified historically (e.g., Lemtrada — one treatment course per authorization; Mavenclad — one course per authorization and two lifetime courses).
    Redirection and denial considerations.

    Providers submitting requests for agents or indications removed from this policy should be redirected to AHCCCS FFS PA criteria; requests for certain non-covered indications (e.g., ocrelizumab for rheumatoid arthritis or lupus nephritis) may be denied if submitted under this policy.

    Non‑FDA approved indications that are not specifically addressed in this policy are excluded from coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with the AHCCCS FFS Prior Authorization Guideline — Coverage of Off‑Label Non‑FDA Approved Indications (the off‑label use policy).

    Ocrelizumab (Ocrevus) is not covered for the indications of rheumatoid arthritis and lupus nephritis/systemic lupus erythematosus due to safety concerns and because the policy has removed Ocrevus as a listed agent and redirected such requests to AHCCCS FFS criteria.

    Use of Ocrevus for rheumatoid arthritis or lupus nephritis/systemic lupus erythematosus is not authorized under this policy and is considered not covered.

    References to indications outside the approved multiple sclerosis diagnoses (for example, rheumatoid arthritis or lupus nephritis) are explicitly noted as not covered in this policy; requests for such indications should follow the off‑label use procedures or be referred to the AHCCCS FFS criteria as applicable.

    Coding and Billing Implications

    Informational coding notemixed
    No codes listed
    Coding Implications - Listed J/Q codesHCPCS
    J1826Injection, interferon beta-1a, 30 mcg.
    Q3027Injection, interferon beta-1a, 1 mcg for intramuscular use.
    Q3028Injection, interferon beta-1a, 1 mcg for subcutaneous use.
    J1830Injection interferon beta-1b, 0.25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered).
    J1595Injection, glatiramer acetate, 20 mg.
    J0202Injection, alemtuzumab, 1 mg.
    J9293Injection, mitoxantrone HCl, per 5 mg.
    J2323Injection, natalizumab, 1 mg.
    J2350Injection, ocrelizumab, 1 mg.
    J9302Injection, ofatumumab, 10 mg.
    Mitoxantrone cumulative lifetime dose
    Mitoxantrone cumulative lifetime dose> 140 mg/m2 (cumulative lifetime)
    Mitoxantrone dosing regimen12 mg/m2 IV every 3 months
    Maximum dose contextLimit applies to cumulative lifetime total, not per-dose maximum
    HCPCS / J-code mappings
    J0202Injection, alemtuzumab, 1 mg (HCPCS/J-code)
    J1595Injection, glatiramer acetate, 20 mg (HCPCS/J-code)
    J1826

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Lemtrada and mitoxantrone. Requests must include documentation elements listed in other callouts; failure to obtain PA may result in denial.

    • Prior authorization required for Lemtrada and mitoxantrone
    • PA must be obtained before dispensing/administration
    Documentation Required

    Documentation Requirement

    Providers must submit supporting documentation such as office chart notes, laboratory results, or claims history showing prior therapies, dates, and durations. Failure to submit required documentation may result in denial or delayed review.

    • Office notes documenting diagnosis and neurologist consultation
    • Lab results when applicable (e.g., baseline labs per product labeling)

    Background and Clinical Context

    Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Management includes disease‑modifying therapies (DMTs) intended to reduce relapse frequency and slow accumulation of disability. Certain agents (for example, alemtuzumab [Lemtrada] and mitoxantrone) are associated with significant safety risks and have specific prescribing, dosing, and monitoring requirements; therefore prior authorization with documentation of diagnosis, prescriber specialty, prior DMT trials, dosing within limits, and evidence of clinical benefit is required for covered agents.

    Definitions and Abbreviations

    Abbreviations
    CISClinically isolated syndrome
    MSMultiple sclerosis
    RRMSRelapsing-remitting multiple sclerosis
    PPMSPrimary progressive multiple sclerosis
    SPMSSecondary progressive multiple sclerosis
    Disease-modifying therapies (Appendix D)
    Interferons and peginterferonInterferon beta-1a, interferon beta-1b, peginterferon beta-1a (Avonex, Rebif, Betaseron, Extavia, Plegridy)
    Policy Summary
    PayerArizona Complete Health
    PolicyMultiple Sclerosis Drugs (Lemtrada, mitoxantrone)
    Policy CodePolicy AZ.CP.PHAR.1020
    Change TypeAlignment and redirectionstreatment-course limits clarified
    Effective Date11.20.19
    Next Review Date
    Key ActionSubmit prior authorization with documentation of diagnosis, neurologist prescriber or consult, age, trials of two DMTs, dosing, and supporting clinical records.
    SourceLink
    On This Page
    Coverage Criteria for Disease-Modifying TherapiesCoding and Billing ImplicationsProvider Requirements and Prior AuthorizationBackground and Clinical ContextDefinitions and Abbreviations
    Injection, interferon beta-1a, 30 mcg (HCPCS/J-code)
    J1830Injection, interferon beta-1b, 0.25 mg (HCPCS/J-code)
    J9293Injection, mitoxantrone HCl, per 5 mg (HCPCS/J-code)
    J2323Injection, natalizumab, 1 mg (HCPCS/J-code)
    J2350Injection, ocrelizumab, 1 mg (HCPCS/J-code)
    J9302Injection, ofatumumab, 10 mg (HCPCS/J-code)
  1. Claims history or medical records showing prior DMT name, start/stop dates, and duration
  2. Documentation Required

    Continued Therapy Documentation

    For continued therapy (re-authorization), include documentation of clinical benefit or positive response to therapy and evidence of ongoing need. For Lemtrada, note that only one treatment course may be approved per authorization; continued-therapy requests must reference prior course and dates. For mitoxantrone, include cumulative dose information and monitoring data.

    • Documentation of positive clinical response (office notes, EDSS or other objective measures when available)
    • For Lemtrada: prior treatment course date(s); continued approval typically limited to 12 months (1 treatment course only)
    • For mitoxantrone: provide cumulative lifetime dose and monitoring (cardiac, labs); approval duration per policy
    Step Therapy

    Step Therapy Requirement

    Step therapy: prior to approval, member must have trial and failure (or documented contraindication/intolerance) to TWO listed disease-modifying therapies (document medication used, date, and duration).

    • Trials must be at least 4 weeks each unless clinical rationale provided
    • List of therapies to try includes (but is not limited to): Avonex, Copaxone, dalfampridine, dimethyl fumarate, fingolimod, Kesimpta, Ocrevus/Ocrevus Zunovo, Rebif, teriflunomide, Tysabri
    • If member has contraindication or intolerance to required agents, provide supporting documentation
    Denial Risk

    Denial Triggers and Redirections

    Denial triggers and redirections: requests for non-covered diagnoses or indications will be denied or redirected per policy. For example, ocrelizumab (Ocrevus) requests for diagnoses such as rheumatoid arthritis or lupus nephritis are not covered under this MS-focused policy and should be redirected to the appropriate policy (e.g., Novantrone or AHCCCS FFS criteria) when applicable.

    • Requests lacking required documentation of prior DMTs, dates, or durations may be denied
    • Requests for non-covered diagnoses will be denied or redirected (e.g., RA or lupus nephritis requests for Ocrevus)
    • Refer to AHCCCS FFS PA criteria for agents/indications removed from this policy
    GlatiramerGlatiramer acetate (Copaxone, Glatopa)
    FumaratesDimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), monomethyl fumarate (Bafiertam)
    Sphingosine modulatorsFingolimod (Gilenya, Tascenso ODT), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory)
    Alkylating / other agentsTeriflunomide (Aubagio), alemtuzumab (Lemtrada), mitoxantrone (Novantrone), natalizumab (Tysabri), ocrelizumab (Ocrevus), cladribine (Mavenclad), ofatumumab (Kesimpta)